ViewRay Stock Surges 2400% on Intraday Rally to €0.025

ViewRay, Inc. (6L9.F) stock exploded 2400% intraday on May 14, 2026, climbing to €0.025 on the XETRA exchange in Germany. The dramatic surge marks an extraordinary single-day move for the Ohio-based medical device manufacturer, which specializes in MRI-guided radiation therapy systems for cancer treatment. Despite the spectacular rally, 6L9.F stock remains deeply underwater from its 52-week high of €4.60, reflecting ongoing investor concerns about the company’s path to profitability and cash burn.

6L9.F Stock Price Action and Technical Levels

ViewRay’s intraday explosion from €0.001 to €0.025 represents one of the most volatile single-day moves in the stock’s recent history. The stock opened at €0.001 and hit a day high of €0.025, with trading volume surging to 3,500 shares compared to its 279-share average daily volume. This 12.5x relative volume spike suggests unusual market activity, though the absolute volume remains thin. Track 6L9.F on Meyka for real-time updates on this volatile medical device stock. The stock trades well below its 50-day average of €0.319 and significantly below its 200-day average of €2.717, indicating a severe downtrend over the past six months.

Financial Metrics Reveal Deep Profitability Challenges

ViewRay’s financial picture remains deeply troubled despite the stock’s intraday rally. The company posted a negative EPS of -€0.55 and a price-to-sales ratio of 2.37, indicating investors are paying for future growth that hasn’t materialized. Operating margins stand at -104.8%, while the net profit margin sits at -105%, meaning the company loses more than one euro for every euro of revenue generated. Free cash flow per share is negative at -€0.529, and the company’s return on equity is -85.2%, reflecting severe operational inefficiency. These metrics underscore why 6L9.F stock has collapsed 99.4% from its 52-week high.

MRIdian Technology and Market Position

ViewRay manufactures the MRIdian system, a cutting-edge MRI-guided radiation therapy platform designed to improve cancer treatment precision while reducing skin toxicity and beam distortion. The company serves university hospitals, community medical centers, private practices, and freestanding cancer facilities across the United States, France, Taiwan, and the United Kingdom. With 2,950 full-time employees and headquarters in Oakwood, Ohio, ViewRay operates in the high-growth medical devices sector. However, the company faces intense competition from established radiation therapy manufacturers and struggles with commercialization challenges that have prevented revenue growth from offsetting operating expenses.

Meyka AI Grade and Investment Outlook

Meyka AI rates 6L9.F with a grade of C+ and a suggestion to HOLD, with a total score of 57.88. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The current ratio of 2.36 shows adequate short-term liquidity, but the debt-to-equity ratio of 1.05 indicates the company relies heavily on debt financing. With a market cap of €207.2 million and 8.29 billion shares outstanding, ViewRay remains a speculative play on innovative cancer therapy technology. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

ViewRay’s 2400% intraday surge to €0.025 reflects extreme volatility in a deeply distressed medical device stock rather than a fundamental turnaround. The company’s persistent losses, negative cash flow, and deteriorating financial metrics paint a picture of a business struggling to commercialize innovative MRI-guided radiation therapy technology. While the MRIdian system addresses real clinical needs in cancer treatment, ViewRay must demonstrate a clear path to profitability and positive cash generation to justify investment at any price level. Investors should approach 6L9.F stock with extreme caution given its speculative nature and ongoing operational challenges.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.